Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Approximately 21.9% of the shares of the company are short sold. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Approximately 21.9% of the shares of the company are short sold.Wall Street Analyst Weigh InA number of equities research analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. Leerink Partnrs raised Immuneering to a "strong-buy" rating in a report on Friday, October 31st. Chardan Capital restated a "buy" rating and set a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immuneering in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.Check Out Our Latest Stock Report on ImmuneeringImmuneering Trading Down 1.3%IMRX stock traded down $0.06 during trading on Friday, hitting $4.58. 1,571,991 shares of the stock traded hands, compared to its average volume of 3,135,325. The stock has a market cap of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering has a one year low of $1.10 and a one year high of $10.08. The company has a 50 day simple moving average of $6.37 and a 200 day simple moving average of $5.78. Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, analysts predict that Immuneering will post -1.86 earnings per share for the current fiscal year. Insider Transactions at ImmuneeringIn related news, Director Peter Feinberg acquired 20,000 shares of the company's stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the acquisition, the director owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have acquired 24,924 shares of company stock valued at $108,400. Company insiders own 22.90% of the company's stock. Institutional Trading of ImmuneeringLarge investors have recently made changes to their positions in the business. Sanofi acquired a new position in shares of Immuneering during the third quarter valued at $18,960,000. Vanguard Group Inc. raised its holdings in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company's stock worth $16,907,000 after purchasing an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC acquired a new position in Immuneering during the 3rd quarter valued at about $6,602,000. Blue Owl Capital Holdings LP bought a new position in shares of Immuneering in the 3rd quarter valued at about $3,850,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Immuneering during the 3rd quarter worth approximately $2,100,000. Institutional investors own 67.65% of the company's stock. Immuneering Company Profile (Get Free Report)Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need. The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.Recommended StoriesFive stocks we like better than ImmuneeringElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietlyExecutive Order 14330: Trump’s Biggest YetNEW LAW: Congress Approves Setup For Digital Dollar?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Immuneering Right Now?Before you consider Immuneering, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here